Terms: = Uterine cancer AND WFDC2, EDDM4, HE4, WAP5, dJ461P17.6 AND Prognosis
24 results:
1. Development and validation of prediction model for early warning of ovarian metastasis risk of endometrial carcinoma.
Zhao Q; Li Y; Wang T
Medicine (Baltimore); 2023 Oct; 102(41):e35439. PubMed ID: 37832099
[TBL] [Abstract] [Full Text] [Related]
2. An analysis of clinical characteristics and prognosis of endometrioid ovarian cancer based on the SEER database and two centers in China.
Chen S; Lu H; Jiang S; Li M; Weng H; Zhu J; Zhang T; Wang Y; Zhao W; Wu D; Shen Z; Yang Z; Zhou Y
BMC Cancer; 2023 Jul; 23(1):608. PubMed ID: 37391693
[TBL] [Abstract] [Full Text] [Related]
3. he4 Tissue Expression as A Putative Prognostic Marker in Low-Risk/Low-Grade Endometrioid Endometrial cancer: A Review.
Mais V; Fais ML; Peiretti M; Fanni D; Massa E; Carboni G; Fais G; Deo G; Angioni S
Curr Oncol; 2022 Nov; 29(11):8540-8555. PubMed ID: 36354733
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic values of human epididymis protein 4 expression in patients with endometrial cancer: A systematic review and meta-analysis.
Han LN; Han YW; Yan P
J Obstet Gynaecol Res; 2022 Sep; 48(9):2255-2269. PubMed ID: 35844088
[TBL] [Abstract] [Full Text] [Related]
5. Prediction of early recurrencies of uterine body cancer based on monitoring of serum biological markers.
Kovalenko NV; Verenikina EV; Maksimov AY; Gladkikh ON; Demidova AA; Domashenko EV
Klin Lab Diagn; 2022 Apr; 67(4):197-203. PubMed ID: 35575391
[TBL] [Abstract] [Full Text] [Related]
6. Serum Human Epididymis Protein 4 as a Prognostic Marker in Cervical cancer.
Hwang WY; Suh DH; Kim K; Kim YB; No JH
Cancer Control; 2022; 29():10732748221097778. PubMed ID: 35506739
[TBL] [Abstract] [Full Text] [Related]
7. Serum he4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma.
Quan Q; Liao Q; Yin W; Zhou S; Gong S; Mu X
Sci Rep; 2021 Nov; 11(1):21694. PubMed ID: 34737393
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic value of serum he4 level in the management of endometrial cancer: A pilot study.
Rajadevan N; McNally O; Neesham D; Richards A; Naaman Y
Aust N Z J Obstet Gynaecol; 2021 Apr; 61(2):284-289. PubMed ID: 33528032
[TBL] [Abstract] [Full Text] [Related]
9. Endometrial cancer: A systematic review of he4, REM and REM-B.
Degez M; Caillon H; Chauviré-Drouard A; Leroy M; Lair D; Winer N; Thubert T; Dochez V
Clin Chim Acta; 2021 Apr; 515():27-36. PubMed ID: 33388311
[TBL] [Abstract] [Full Text] [Related]
10. he4 tumor marker as a predictive factor for lymphatic metastasis in endometrial cancer.
Espiau Romera A; Cuesta Guardiola T; Benito Vielba M; De Bonrostro Torralba C; Coronado Martín PJ; Baquedano Mainar L
Int J Gynaecol Obstet; 2020 Jun; 149(3):265-268. PubMed ID: 32147821
[TBL] [Abstract] [Full Text] [Related]
11. Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: A meta-analysis.
Li J; Wang X; Qu W; Wang J; Jiang SW
Clin Chim Acta; 2019 Jan; 488():215-220. PubMed ID: 30414437
[TBL] [Abstract] [Full Text] [Related]
12. he4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients.
Abbink K; Zusterzeel PL; Geurts-Moespot AJ; Herwaarden AEV; Pijnenborg JM; Sweep FC; Massuger LF
Tumour Biol; 2018 Feb; 40(2):1010428318757103. PubMed ID: 29463191
[TBL] [Abstract] [Full Text] [Related]
13. Novel algorithm including CA-125, he4 and body mass index in the diagnosis of endometrial cancer.
Knific T; Osredkar J; Smrkolj Š; Tonin I; Vouk K; Blejec A; Frković Grazio S; Rižner TL
Gynecol Oncol; 2017 Oct; 147(1):126-132. PubMed ID: 28735628
[TBL] [Abstract] [Full Text] [Related]
14. Serum he4 is correlated to prognostic factors and survival in patients with endometrial cancer.
Stiekema A; Lok C; Korse CM; van Driel WJ; van der Noort V; Kenter GG; Van de Vijver KK
Virchows Arch; 2017 Jun; 470(6):655-664. PubMed ID: 28401338
[TBL] [Abstract] [Full Text] [Related]
15. Serum he4 Level as a Biomarker to Predict the Recurrence of Gynecologic cancers.
Li J; Chen H; Curcuru JR; Patel S; Johns TO; Patel D; Qian H; Jiang SW
Curr Drug Targets; 2017; 18(10):1158-1164. PubMed ID: 28382859
[TBL] [Abstract] [Full Text] [Related]
16. Further insight into prognostic factors in endometrial cancer: the new serum biomarker he4.
Capriglione S; Plotti F; Miranda A; Lopez S; Scaletta G; Moncelli M; Luvero D; De Cicco Nardone C; Terranova C; Montera R; Angioli R
Expert Rev Anticancer Ther; 2017 Jan; 17(1):9-18. PubMed ID: 27892774
[TBL] [Abstract] [Full Text] [Related]
17. Discovery of biomarkers for endometrial cancer: current status and prospects.
Rižner TL
Expert Rev Mol Diagn; 2016 Dec; 16(12):1315-1336. PubMed ID: 27817223
[TBL] [Abstract] [Full Text] [Related]
18. Physiopathological factors affecting the diagnostic value of serum he4-test for gynecologic malignancies.
Qu W; Li J; Duan P; Tang Z; Guo F; Chen H; Zhu X; Jiang SW
Expert Rev Mol Diagn; 2016 Dec; 16(12):1271-1282. PubMed ID: 27784171
[TBL] [Abstract] [Full Text] [Related]
19. Expression of he4 in Endometrial cancer and Its Clinical Significance.
Li X; Gao Y; Tan M; Zhuang H; Gao J; Hu Z; Wang H; Zhu L; Liu J; Lin B
Biomed Res Int; 2015; 2015():437468. PubMed ID: 26539494
[TBL] [Abstract] [Full Text] [Related]
20. Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma.
Deng L; Gao Y; Li X; Cai M; Wang H; Zhuang H; Tan M; Liu S; Hao Y; Lin B
J Exp Clin Cancer Res; 2015 Sep; 34(1):96. PubMed ID: 26362938
[TBL] [Abstract] [Full Text] [Related]
[Next]
